

PRESS RELEASE

deltaDOT chosen as supplier to National Center for Therapeutics Manufacturing, College Station, Texas

London, UK, 18 December 2013 - deltaDOT Ltd announced today that the sale of deltaDOT's HPCE-512 instruments to the Texas A&M Center for Innovation in Advanced Development and Manufacturing (CIADM). The implementation of the HPCE-512 technology at the CIADM will facilitate the establishment of enhanced analytical capabilities in the Center's facilities.

The Texas A&M Center for Innovation is home to the National Center for Therapeutics Manufacturing (NCTM) located in Bryan-College Station, Texas. The HPCE-512 units purchased by the Texas A&M Center will support the development, manufacture, and testing of vaccines and therapeutics in the event of a public health emergency.

"The primary objective of the CIADM is to enhance the United States' emergency preparedness capabilities against emerging infectious diseases and other chemical, biological, radiological, and nuclear threats. The addition of deltaDOT's technology will support the manufacture and release of the medical countermeasures that are required to combat these threats in a more timely and cost-effective manner," says CIADM Principal Investigator, Dr. Gerald Parker.

The Center for Innovation and NCTM personnel are enthusiastic about the opportunity to incorporate deltaDOT's technology into its suite of capabilities and are confident it will significantly contribute to the Center's ability to perform the analytics that are required to support the bioprocessing and quality assurance of therapeutics and vaccines in accordance with US Food and Drug Administration (FDA) regulations.

Dr Stuart Hassard, deltaDOT's Chief Scientific Officer commented on the sale: "The sale of our instruments to the Texas A&M CIADM has been achieved after an extensive evaluation of the data produced by the HPCE-512 instrument by this client. The rapid production of data by the HPCE-512, combined with our automated sample handling, is ideal for meeting the CIADM's leading edge requirements. The project also has an extensive educational remit and we are pleased that the next generation of U.S. scientists will be introduced to our technology early in their careers."

The HPCE-512 analyzes proteins, peptides, nucleic acids, amino acids and small molecules. By incorporating deltaDOT's Label Free Intrinsic Imaging technology (LFII®), the HPCE-512 is able to monitor unlabelled biomolecules directly, in real time, in a highly cost effective manner. The system uses advanced signal processing

deltaDOT's HPCE-512 instrument



tools to identify the unlabelled analyte, providing unprecedented resolution, quantification and repeatability of analysis.

More about deltaDOT Ltd

deltaDOT has developed and commercialised highly innovative instrumentation for the life sciences sector based on an innovative approach to Capillary Electrophoresis (**CE**). deltaDOT's patented multipoint sensor system together with the proprietary computing algorithms gives superior resolution, accuracy and repeatability. This is High Performance Capillary Electrophoresis (**HPCE**) at its best - Label Free Intrinsic Imaging (**LFII**[®]). deltaDOT technology has found successful applications in detection, separation and analysis of proteins, nucleic acids, carbohydrates, viruses and bacteria, drugs, chemicals and a wide range of other analytes.

Find out more about deltaDOT Ltd at <http://www.deltadot.com>

Mr. Nigel Stokes, Managing Director

deltaDOT Ltd.

+44 (0)207 691 4919

n.stokes@deltadot.com

About The Texas A&M Center for Innovation

The Texas A&M Center for Innovation in Advance Development and Manufacturing (CIADM) is one of three centers established in June, 2012 by the US Department of Health and Human Services to enhance the nation's emergency preparedness against emerging infectious diseases, including pandemic influenza, and chemical, biological, radiological and nuclear threats. The Center is founded on an initial \$285.6 million investment, including a \$176.6 million contribution from the US Department of Health and Human Services, with the remainder cost-shared by commercial and academic proposal partners.

The Center will perform research and advanced development to accelerate vaccines and other medical products through pre-clinical and clinical development and produce these products in cases of pandemics or other national emergencies. Through these activities, the Center will address a recognized shortcoming in preparedness and response to known and unknown threats, and will improve our nation's ability to protect the health of its citizens in emergency situations. TAMUS also will utilize CIADM capabilities to develop and transition platform technologies to accelerate new treatments for conditions as diverse as cancer and cardiovascular disease.

Patricia Haigwood

979-436-9106

haigwood@tamhsc.edu